Your Shopping Cart Is Empty
| Report Code: A12303 | Aug 2022 | Pages: 324 | ||
| Tables: 214 | Charts: 68 |
| |
The global opioid use disorder market was valued at $2.8 billion in 2021, and is projected to reach $8.1 billion by 2031, growing at a CAGR of 11.5% from 2022 to 2031. Opioids are a group of painkillers that include drugs that relax muscles, reduce pain, and relieve stress. Medications including hydrocodone, oxycodone, codeine, fentanyl, methadone, morphine, and other pharmaceutical opioids are prescribed to relieve moderate- to severe pain. The chronic, relapsing brain illness known as opioid usage disorder (OUD) is characterized by excessive opioid seeking and use despite side effects. It is regarded as a brain condition because it involves functional changes to brain circuits related to motivation, stress, self-control, and decision-making, and because those changes may endure for a considerable amount of time after drug use has stopped. An overwhelming want to use opioids, increased opioid tolerance, and withdrawal symptoms after cessation are all symptoms of opioid use disorder.
The COVID-19 outbreak is anticipated to have a negative impact on growth of the global opioid use disorder market. The COVID-19 pandemic has stressed healthcare systems of the world. A huge number of clinics, hospitals across the globe, were restructured to increase the hospital capacity for the patient diagnosed with COVID-19. Moreover, the postponement or cancellation of doctor appointments has severely affected the market. Decrease in the number of scheduled surgeries anticipated to decrease in demand of opioids which cause decrease in the prevalence of opioid use disorder. Thus, these factors are anticipated to hinder the growth of market.
Growth of the global opioid use disorder market size is majorly driven by rise in the prevalence of chronic diseases such as cancer, cardiovascular diseases and orthopedic diseases anticipated to drive the opioid use disorder market growth. Increase in the number of chronic diseases cause rise in the incidence of surgical intervention. Opioid drugs are used to treat pain after surgery. This factor can cause addiction of opioid drugs even after decrease in pain. Thus, rise in the prevalence of chronic diseases anticipated fuel the demand of opioids use disorder drugs which boosts the market growth. For instance, as per the report of the National Cancer Institute, in 2020, an estimated 1,806,590 new cases of cancer were diagnosed in the U.S.
Moreover, rise in product launch and product approval for opioid use disorder drugs anticipated to fuel the growth of opioid use disorder market. For instance, in May 2020, Indivior PLC, a pharmaceutical company in U.S., announced the approval of Subutex from Swedish Medical Products Agency (MPA). Subutex prolonged release solution for injection, 100 and 300mg for substitution treatment of opioid dependence in adults and adolescents over 16 years of age. Moreover, in February 2019, Indivior PLC, a pharmaceutical company, announced the launch of generic version of SUBOXONE (buprenorphine and naloxone) Sublingual Film (CIII) in the U.S. used to treat opioid use disorders.
In addition, rising consideration of buprenorphine patches as an effective treatment mode fuels the market growth. Buprenorphine patches are becoming increasingly popular as an effective treatment for opioid use disorder, which is anticipated to the growth of opioid use disorder market. Patches containing buprenorphine are regarded as a cutting-edge method for treating opioid use disorder. Transdermal patches offer a number of benefits over other forms of treatment, such as injections, including the most pleasant drug delivery system, excellent pain relief, and self-administration of drug. In addition, rise in adoption of key strategies such as collaboration, acquisition, agreement and partnership by opioid industry of opioids use disorder fuels the growth of market. For instance, in February 2019, Indivior PLC, a pharmaceutical company, announced agreement with Alvogen Pine Brook LLC, a pharmaceutical company for sell of generic buprenorphine and naloxone sublingual film product unless and until the U.S. On the other hand, side effects associated opioids use disorder drugs anticipated to hinder the growth of opioid use disorder market growth.
Opioid Use Disorder Market Segmentation
The opioid use disorder market size is segmented into drug type, age group, route of administration and distribution channal, and region. On the basis of type, the market is segmented into agonist and antagonist. The agonist segment further sub-categorized into methadone and buprenorphine. Depending on age group, the market is classified into 19-39, 40-59 and age 60 and over. By route of administration, the market is classified into oral, intravenous and sublingual. On the basis of distribution channel, the market is divided into hospital pharmacy, retail pharmacy. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Segment Review
The agonist segment dominated the opioid use disorder market share in 2021, and is expected to continue this trend throughout the forecast period, owing to Rise in the prevalence of chronic pain, high prevalence of opioid abuse and rising geriatric population prone to painful disease. However, antagonist segment is expected to witness considerable growth during the opioid use disorder market forecast period, owing to increase in research & development expenditure by major players, strategic alliances among key companies, and ongoing research on naltrexone drugs.
The 19 to 39 segment dominated the market in 2021, and is expected to continue this trend throughout the forecast period, owing to rise in the prevalence of chronic diseases such as cancer, cardiovascular diseases and orthopedic diseases associated with chronic pain.
The intravenous segment dominated the market in 2021, and is expected to continue this trend throughout the forecast period, owing to rise in the demand of intravenous route for the treatment of opioids use disorder treatment.
The hospital pharmacy segment dominated the market in 2021, and is expected to continue this trend throughout the forecast period, owing to rise in number of hospital pharmacy, increase in expenditure by government to develop healthcare infrastructure and increase in the prevalence of opioids use disorder.
The North America market was dominant, in terms of revenue among other regions in 2021, owing to increase the number of product launch and product approval for opioids use disorder, increase in the prevalence of chronic diseases such as cancer, cardiac diseases and orthopedic diseases and well-established opioid industry in North America. On the other hand, Asia-Pacific was the second-largest contributor in the market in 2021, and is expected to register fastest CAGR during the forecast period, owing to the number of geriatric populations, rise in the awareness regarding availability of healthcare services and increase in the number of chronic diseases.    Â
Some of the major companies that operate in the global opioid use disorder market include Alkermes, AstraZeneca Plc., BioDelivery Sciences International Inc., Braeburn, Camurus, Cerebral, Dr Reddy, Hikma Pharmaceuticals PLC, Indivior PLC, Mallinckrodt Pharmaceuticals, NYC Health + Hospitals, Orexo AB, Pear Therapeutics, Pfizer, Reckitt Benckiser Pharmaceuticals Inc., Sandoz (Novartis), Titan Pharmaceuticals, Inc., Viatris Inc.                       Â
Opioid Use Disorder Market Report Highlights
| Aspects | Details |
|---|---|
| By Drug Type |
|
| By Age group |
|
| By Route of Administration |
|
| By Distribution channal |
|
| By Region |
|
| Key Market Players | Dr Reddy Laboratories Ltd, Indivior PLC, Alkermes, Inc., AstraZeneca plc, mallinckrodt pharmaceuticals, Pear Therapeutics, OREXO AB, Camurus, Viatris Inc, Reckitt Benckiser Pharmaceuticals Inc, BioDelivery Sciences International Inc.,, Titan Pharmaceuticals, Inc., Orexo AB, Hikma Pharmaceuticals PLC,, braeburn pharmaceuticals, Sandoz, NYC Health Hospitals |
Opioid use disorder consists of an overpowering desire to use opioids, increased opioid tolerance, and withdrawal syndrome when discontinued. The opioid use disorder market is expected to witness growth during the forecast period owing to, rise in the prevalence of chronic diseases such as cardiovascular disease, cancer and others, increase in the product launch and product approval for opioids use disorder drugs and increasing cases of opioid addiction.
Rise in adoption of key strategies such as collaboration, acquisition, agreement and partnership by key players of opioids use disorder fuels the growth of market. For instance, in February 2019, Indivior PLC, a pharmaceutical company, announced agreement with Alvogen Pine Brook LLC, a pharmaceutical company for sell of generic buprenorphine and naloxone sublingual film product unless and until the U.S. Moreover, in February 2021, Orexo AB announced its collaboration with ApexB.io biotechnology research company to further research on the use of Modia. This product is a digital therapeutic designed for patients with opioid use disorder
A. The top companies that hold the market share in opioid use disorder market are increase in number of patients suffering from wide range of severe and chronic diseases such as cancer, cardiovascular disease, pain arising from injuries and other conditions
A. Asia-Pacific is expected to register highest CAGR of 12.3% from 2022 to 2031, owing to the number of geriatric populations, rise in the awareness regarding availability of healthcare services and increase in the number of chronic diseases.
A. The key trends in the opioid use disorder market are Alkermes, AstraZeneca Plc., BioDelivery Sciences International Inc., Braeburn, Camurus, Cerebral, Dr Reddy, Hikma Pharmaceuticals PLC, Indivior PLC, Mallinckrodt Pharmaceuticals, NYC Health + Hospitals, Orexo AB, Pear Therapeutics, Pfizer, Reckitt Benckiser Pharmaceuticals Inc., Sandoz (Novartis), Titan Pharmaceuticals, Inc., and Viatris Inc.,
A. The base year for the report is 2021.
A. Yes, opioid use disorder companies are profiled in the report
A. The total market value of opioid use disorder market is $2,750.5 million in 2021.
A. The forecast period in the report is from 2022 to 2031
A. The market value of opioid use disorder market in 2022 was $3,059.4 million
Start reading instantly.
This Report and over 66,804+ more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Contact Details
Need to talk to an expert? Book your free consultation and let our research experts help you with your needs/problems.
Global Report 
Regional Report
Country Report
Related Report